Abstracts tagged "interstitial lung disease"

Abstract Number: 1643 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease: Subgroup Analysis of the SENSCIS Trial by Corticosteroid Use
Madelon Vonk¹, Oliver Distler ², Daniel Furst ³, Eric Hachulla ⁴, Sindhu Johnson ⁵, Shervin Assassi ⁶, Leslie Meng ⁷, Manuel Quaresma ⁸, Margarida Alves ⁸, Emmanuelle Clerisme-Beaty ⁸ and Wim Wuyts ⁹, ¹Department of Rheumatology, Radboud University Medical Center, Nijmegen, The Netherlands, Nijmegen, Gelderland, Netherlands, ²Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland, ³University of California, Los Angeles, CA, ⁴Dept. of Internal Medicine and Clinical Immunology, Hôpital Claude Huriez, University of Lille, Lille, France, Lille, France, ⁵Toronto Scleroderma Program, Department of Medicine, Toronto Western and Mount Sinai Hospitals, University of Toronto, Toronto, Canada, Toronto, Canada, ⁶Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, Texas, USA, Houston, TX, ⁷Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA, Ridgefield, ⁸Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ⁹Unit for Interstitial Lung Diseases, Department of Respiratory Medicine, University Hospitals Leuven, Leuven, Belgium, Leuven, Belgium
Background/Purpose: In the SENSCIS trial in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD), nintedanib reduced the rate of decline in forced vital capacity (FVC)…
Abstract Number: 2340 • 2019 ACR/ARP Annual Meeting
Treatment of Interstitial Lung Disease and Airway Disease Complicated with Rheumatoid Arthritis
Takeshi Shoda¹, Tohru Takeuchi ², Takuya Kotani ², Koji Nagai ², Kennichiro Hata ², Shigeki Makino ² and Shigeki Arawaka ², ¹Yodogawa christian hospital / Osaka medical college, Osaka, Japan, ²Osaka medical college, Osaka, Japan
Background/Purpose: Interstitial lung disease (ILD) complicated with rheumatoid arthritis (RA) is detected in 27 to 67% of patients on high-resolution computed tomography (HRCT), and airway…
Abstract Number: 374 • 2019 ACR/ARP Annual Meeting
The INBUILD Trial of Nintedanib in Patients with Progressive Fibrosing Interstitial Lung Diseases: Subgroup with Autoimmune Diseases
Eric Matteson¹, Clive Kelly ², Jörg Distler ³, Anna Maria Hoffmann-Vold ⁴, James Seibold ⁵, Shikha Mittoo ⁶, Oliver Distler ⁷, Rainer-Georg Goeldner ⁸, Rozsa Schlenker-Herceg ⁹, Susanne Stowasser ¹⁰, Manuel Quaresma ¹⁰ and Kevin Flaherty ¹¹, ¹Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA, Rochester, ²Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK, Newcastle, United Kingdom, ³Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, Erlangen, Germany, ⁴Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, ⁵Scleroderma Research Consultants LLC, Aiken, South Carolina, USA, Aiken, ⁶University Health Network, Toronto, Ontario, Canada, Toronto, Canada, ⁷Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland, ⁸Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany, Biberach, Germany, ⁹Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA, Ridgefield, ¹⁰Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ¹¹University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, MI
Background/Purpose: Some patients with autoimmune disease develop progressive fibrosing interstitial lung disease (ILD) characterized by increasing fibrosis on HRCT, decline in lung function, worsening symptoms…
Abstract Number: 1644 • 2019 ACR/ARP Annual Meeting
Effects of Nintedanib in Patients with Diffuse and Limited Cutaneous Systemic Sclerosis and Interstitial Lung Disease: Subgroup Analysis of the SENSCIS Trial
Masataka Kuwana¹, Kristin Highland ², Martina Gahlemann ³, Christopher Denton ⁴, Aryeh Fischer ⁵, Maureen Mayes ⁶, Virginia Steen ⁷, Dinesh Khanna ⁸, Yannick Allanore ⁹, Mannaig Girard ¹⁰, Margarida Alves ¹¹, Susanne Stowasser ¹¹ and Oliver Distler ¹², ¹Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, Bunkyo-ku, Tokyo, Japan, ²Cleveland Clinic, Cleveland, Ohio, USA, Cleveland, OH, ³Boehringer Ingelheim (Schweiz) GmbH, Basel, Switzerland, Basel, Switzerland, ⁴University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, UK, London, United Kingdom, ⁵University of Colorado School of Medicine, Denver, Colorado, USA, Denver, CO, ⁶Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, Texas, USA, Houston, TX, ⁷Georgetown University, Washington, D.C., USA, Georgetown, ⁸Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, ⁹Dept. of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France, Paris, France, ¹⁰Boehringer Ingelheim France S.A.S., Reims, France, Reims, France, ¹¹Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ¹²Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland
Background/Purpose: Patients with diffuse cutaneous systemic sclerosis (dcSSc) are at greater risk of developing interstitial lung disease (ILD) than patients with limited cutaneous systemic sclerosis…
Abstract Number: 2341 • 2019 ACR/ARP Annual Meeting
Findings of Pulmonary Abnormalities on High Resolution Computed Tomography in a Cohort of Rheumatoid Arthritis Patients Without Known Lung Disease
Scott Matson¹, Kevin Deane ², Christopher Collora ¹, Xi Zheng ¹, Marie Fester ¹, Joyce Lee ¹ and M. Kristen Demoruelle ³, ¹University of Colorado, Denver, ²University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Aurora, CO, ³University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Aurora
Background/Purpose: Pulmonary manifestations of rheumatoid arthritis (RA) lead to significant morbidity and mortality. Lung manifestations in RA are myriad, however little is known about how…
Abstract Number: 385 • 2019 ACR/ARP Annual Meeting
Distinctive Clinical Features and Biomarkers of Connective Tissue Disease Associated Interstitial Lung Disease
Sang Wan Chung¹, So-Yun Lee ¹, Sang-Hoon Lee ¹, Seung-Jae Hong ¹ and Yeon-Ah Lee ¹, ¹School of Medicine, Kyung Hee University, seoul, Republic of Korea
Background/Purpose: The connective tissue diseases (CTD) are a group of rheumatologic diseases characterized by inflammation and immune-mediated organ damage including interstitial lung disease (ILD). The…
Abstract Number: 1648 • 2019 ACR/ARP Annual Meeting
Systemic Sclerosis Auto-antibody Profiles Predict Interstitial Lung Disease Onset but Not Progression
Boyang Zheng¹, Mianbo Wang ², Marvin Fritzler ³, May Choi ³, Murray Baron ⁴ and Marie Hudson ⁵, ¹Jewish General Hospital, McGill University, Montreal, QC, Canada, ²Lady Davis Institute, Jewish General Hospital, Montreal, QC, Canada, ³Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁴Jewish General Hospital, McGill University, Montreal, Canada, ⁵Jewish General Hospital, Lady Davis Institute for Medical Research, and Department of Medicine, McGill University, Montreal, QC, Canada
Background/Purpose: Interstitial lung disease (ILD) is frequent manifestation and a leading cause of mortality in systemic sclerosis (SSc). Some SSc-related autoantibodies (aAbs), especially anti-topoisomerase I…
Abstract Number: 2342 • 2019 ACR/ARP Annual Meeting
Association of Serum KL-6 Level and Change of Pulmonary Function in Interstitial Lung Disease of Rheumatoid Arthritis – Data from Prospective KOrean Rheumatoid Arthritis Interstitial Lung Disease (KORAIL) Study
Jeong Seok Lee¹, Young Im Yoon ², Eun Young Lee ³, Jung Yoon Choe ⁴, Hwa Jung Lee ⁵, Yong-Beom Park ⁶, Eun Ha Kang ⁷, You-Jung Ha ⁷, Yeon-Ah Lee ⁸ and Seong Hye Jang ⁹, ¹Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea, ²Seoul National University Hospital, Seoul, Republic of Korea, ³Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Seoul, Republic of Korea, ⁴Division of Rheumatology, Daegu Catholic University Medical Center, Daegu, Republic of Korea, ⁵DAEGU CATHOLIC UNIVERSITY, Daegu, Republic of Korea, ⁶Yonsei university college of medicine, severance hospital, Seodaemun-gu, Seoul-t'ukpyolsi, Republic of Korea, ⁷Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea, Seongnam, Republic of Korea, ⁸School of Medicine, Kyung Hee University, Seoul, Republic of Korea, ⁹Soonchunhyang University, Cheonan, Republic of Korea
Background/Purpose: Interstitial lung disease (ILD) is the most common lung disease among rheumatoid arthritis (RA) patients. Although the overall mortality rates for RA have decreased…
Abstract Number: 708 • 2019 ACR/ARP Annual Meeting
Improvement and Stabilization of Lung Function in Patients with SSc-ILD Treated with Nintedanib vs Placebo in a Randomized, Placebo-Controlled Phase III Trial: Proportions of Patients with FVC Changes Using Cutoffs Previously Proposed to Define Minimally Clinically Important Differences
Yannick Allanore¹, Dinesh Khanna ², Elizabeth Volkmann ³, Christian Stock ⁴, Martina Gahlemann ⁵, Nils Schoof ⁶, Oliver Distler ⁷ and Toby Maher ⁸, ¹Dept. of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France, Paris, France, ²Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, ³University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, ⁴Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ⁵Boehringer Ingelheim (Schweiz) GmbH, Basel, Switzerland, Basel, Switzerland, ⁶Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, ⁷Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland, ⁸National Heart and Lung Institute, Imperial College London, UK and National Institute for Health Research Clinical Research Facility, Royal Brompton Hospital, London, UK, London, United Kingdom
Background/Purpose: Mean change in forced vital capacity percent predicted (FVC %pred) is a common endpoint in the assessment of treatment-related outcomes in patients with interstitial…
Abstract Number: 1649 • 2019 ACR/ARP Annual Meeting
Mycophenolate Mofetil and Cyclophosphamide Improve Health-Related Quality of Life in Patients with Systemic Sclerosis Who Participated in SLS II
Elizabeth Volkmann¹, Donald Tashkin ², Michael Roth ³, Holly LeClair ², Philip Clements ², Daniel Furst ⁴, Robert Elashoff ² and Dinesh Khanna ⁵, ¹University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, ²University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, ³University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁴University of California, Los Angeles, CA, ⁵Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor
Background/Purpose: Interstitial lung disease (ILD) is the leading cause of morbidity and mortality in systemic sclerosis (SSc). The majority of studies investigating novel therapies for…
Abstract Number: 2344 • 2019 ACR/ARP Annual Meeting
Efficacy of Mycophenolate Mofetil in the Treatment of Rheumatoid Arthritis Associated Interstitial Lung Disease
Jonathan Amos¹, Jennifer Kendall ¹, Robyn Moran ², Megan Krause ³, Paul Schmidt ⁴, Chase Hall ⁵, Mark Hamblin ⁶ and Mehrdad Maz ⁷, ¹University of Kansas Medical Center, Division of Rheumatology, KANSAS CITY, KS, ²University of Kansas Medical Center, Kansas City, KS, ³University of Kansas, KANSAS CITY, KS, ⁴University of Kansas Medical Center, Division of Rheumatology, Kansas City, ⁵University of Kansas Medical Center, Division of Pulmonary and Critical Care, KANSAS CITY, ⁶University of Kansas Medical Center, Division of Pulmonary and Critical Care, Kansas City, KS, ⁷The University of Kansas Medical Center, KANSAS CITY, KS
Background/Purpose: Interstitial lung disease (ILD) as an extra-articular manifestation of rheumatoid arthritis (RA) leads to significant morbidity and mortality. As data is limited, this study…
Abstract Number: 712 • 2019 ACR/ARP Annual Meeting
Safety and Tolerability of Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease in the SENSCIS Trial: Subgroup Analysis Based on Demographic Characteristics
Oliver Distler¹, Kristin Highland ², Maureen Mayes ³, Masataka Kuwana ⁴, Lesley Saketkoo ⁵, Madelon Vonk ⁶, Michael Kreuter ⁷, Laura Hummers ⁸, Ute von Wangenheim ⁹, Martina Gahlemann ¹⁰, Veronika Kohlbrenner ¹¹, Margarida Alves ¹², Emmanuelle Clerisme-Beaty ¹² and Arata Azuma ¹³, ¹Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland, ²Cleveland Clinic, Cleveland, Ohio, USA, Cleveland, OH, ³Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, Texas, USA, Houston, TX, ⁴Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, Bunkyo-ku, Tokyo, Japan, ⁵New Orleans Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans; Tulane University School of Medicine, University Medical Center – Comprehensive Pulmonary Hypertension Center, USA, New Orleans, ⁶Department of Rheumatology, Radboud University Medical Center, Nijmegen, The Netherlands, Nijmegen, Gelderland, Netherlands, ⁷Center for Interstitial and Rare Lung Diseases, Pneumology, Thoraxklinik, University of Heidelberg, Member of the German Center for Lung Research, Germany, Germany, Germany, ⁸Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, USA, Baltimore, MD, ⁹Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany, Biberach an der Riss, ¹⁰Boehringer Ingelheim (Schweiz) GmbH, Basel, Switzerland, Basel, Switzerland, ¹¹Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA, Ridgefield, ¹²Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ¹³Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan, Tokyo, Japan
Background/Purpose: In the SENSCIS trial in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD), the adverse events associated with nintedanib were manageable for most patients…
Abstract Number: 1654 • 2019 ACR/ARP Annual Meeting
Esophageal Dilation and Other Clinical Factors Associated with Pulmonary Function Decline in Patients with Systemic Sclerosis
Kimberly Showalter¹, Aileen Hoffmann ², Carrie Richardson ³, Kimberly Koloms ², Gerald Rouleau ², David Aaby ², Julia (Jungwha) Lee ⁴, Jane Dematte ², Rishi Agrawal ², Xiaoping Wu ⁵, Rowland Chang ⁴ and Monique Hinchcliff ⁶, ¹Hospital for Special Surgery, New York, NY, ²Northwestern University Feinberg School of Medicine, Chicago, ³Rush University, Chicago, ⁴Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵New York Presbyterian/Weill Cornell, New York, ⁶Yale University, Section of Rheumatology, Allergy and Immunology, New Haven, CT
Background/Purpose: Prior work has shown that Scl-70 positive autoantibody status and baseline c-reactive protein (CRP) are associated with more rapid pulmonary function decline in patients…
Abstract Number: 2345 • 2019 ACR/ARP Annual Meeting
Abatacept in Rheumatoid Arthritis with Interstitial Lung Disease: A Retrospective Multicenter Study of 263 Patients
C. Fernández-Díaz¹, Rafael Melero ², Javier Loricera ³, Santos Castañeda ⁴, Francisco Ortiz-Sanjuán ⁵, I. Casafont-Solé ⁶, Carmen carrasco-Cubero ⁷, A. Juan-Mas ⁸, Raquel Almodovar-Gonzalez ⁹, S. Rodriguez-Garcia ¹⁰, R. Castellanos ¹¹, O. Maiz-Alonso ¹², C. Aguilera-Cros ¹³, I. Cabezas-rodriguéz ¹⁴, EC Cervantes ¹⁵, M. Moreno ¹⁶, L. Arboleya ¹⁷, C. Montagut ¹⁸, Patricia Carreira ¹⁹, C. Ojeda-Garcia ²⁰, Gema Bonilla ²¹, T. Perez-Sandoval ²², P. Vela ²³, JL Andreu ²⁴, Susana Romero-Yuste ²⁵, A. Urruticoechea-Arana ²⁶, E. Salgado-Pérez ²⁷, Cristina Hidalgo ²⁸, Javier Narváez ²⁹, E. Raya ³⁰, MJ. Moreno-Ramos ³¹, P. Morales-Garrido ³², L. Pérez-alba ³³, Carlos Fernández-López ³⁴, Ignacio Villa ³⁵, Noelia Álvarez-Rivas ³⁶, Juan María Blanco-Madrigal ³⁷, JR Jimenez-Aberasturi ³⁸, A. Perez-Linaza ³⁹, N. Del-val-del-amo ⁴⁰, Sabela Fernández ⁴¹, A. García-valle ⁴², C.A. Peralta-Ginés ⁴³, A. Garcia-Aparicio ⁴⁴, L. Exposito-pérez ⁴⁵, N. Mena-Vazquez ⁴⁶, R. López-Sánchez ⁴⁷, B. Garcia-magallon ⁴⁸, Miguel Angel González-Gay ⁴⁹ and Ricardo Blanco ⁵⁰, ¹HU Vinalopo, Madrid, Madrid, Spain, ²Complexo Hospitalario Universitario de Vigo, Vigo, Galicia, Spain, ³Rheumatology Department. Hospital Marqués de Valdecilla, Santander, Cantabria, Spain, ⁴Rheumatology Department, Hospital Universitario de la Princesa, IIS-Princesa, Madrid, Spain, Madrid, Spain, ⁵Hospital Universitario y Politécnico La Fe, Valencia, Comunidad Valenciana, Spain, ⁶HU German Trias i pujol, BAacelona, ⁷CHU de Badajoz, Badajoz, Spain, ⁸H Son Llázer, Palma de Mallorca, Islas Baleares, Spain, ⁹Hospital Universitario Fundación Alcorcón, Madrid, Spain, ¹⁰HU. Clinic, Barcelona, ¹¹Fundacio Clinic. Hospital Clinic de Barcelona, Barcelona, Spain, ¹²HU Donostia, Donostia, Spain, ¹³hospital virgen del rocio, Sevilla, Spain, ¹⁴HU. Río Hortega, Valladolid, Spain, ¹⁵HU Santiago de compostela, Santiago, ¹⁶Parc Tauli Hospital Universitari, Sabadell, Spain, ¹⁷Hospital Central Asturias, OViedo, ¹⁸HCU Valladolid, Valladolid, Spain, ¹⁹Hospital Universitario 12 de Octubre, Madrid, Spain, ²⁰HU Virgen de la Macarena, Sevilla, ²¹Rheumatology Department, Hospital Universitario La Paz, Madrid, Spain, Madrid, Spain, ²²HU León, León, Spain, ²³Hospital General Universitario de Alicante, Alicante, Comunidad Valenciana, Spain, ²⁴HU Puerta del Hierro, Madrid, ²⁵Complejo Hospitalario Universitario Pontevedra, Pontevedra, Galicia, Spain, ²⁶HU Can Misses, Ibiza, Spain, ²⁷C.H Ourense, Ourense, ²⁸Hospital Clínico Universitario de Salamanca, Salamanca, Castilla y Leon, Spain, ²⁹Rheumatology Department, Hospital Universitario de Bellvitge, Barcelona, Spain, Barcelona, Catalonia, Spain, ³⁰Hospital San Cecilio, Granada, Andalucia, Spain, ³¹HU Arrixaca, Murcia, Spain, ³²Hospital San Cecilio, Granada, Spain, ³³HU San Cecilio, Granada, Spain, ³⁴Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 15006. A Coruña, España, A Coruña, Spain, ³⁵Hospital de Sierrallana, Torrelavega, Cantabria, Spain, ³⁶Hospital Universitario Lucus Augusti, Lugo, Galicia, Spain, ³⁷Rheumatology Unit, Basurto University Hospital, Bilbao, Spain, Bilbao, Spain, ³⁸HU Araba, Vitoria, Spain, ³⁹HU Puerta del Mar, Cadiz, ⁴⁰HU Navarra, Pamplona, Spain, ⁴¹Hospital Universitario San Agustín, Avilés, Asturias, Spain, ⁴²Rheumatology Department. Hospital Rio Carrión, Palencia, Spain, ⁴³HU Lozano Blesa, Zaragoza, ⁴⁴H Virgen de la salud, Toledo, Spain, ⁴⁵HU Canarias, Tenerife, Spain, ⁴⁶HU Malaga., Malaga, ⁴⁷Hospital Negrin, Tenerife, ⁴⁸H Huesca, HUesca, ⁴⁹Universidad de Cantabria and IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁵⁰Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Spain
Background/Purpose: Interstitial Lung Disease (ILD) is a severe extraarticular manifestation of rheumatoid arthritis (RA).Interstitial lung disease (ILD) associated with Rheumatoid Arthritis (RA) has a poor…
Abstract Number: 737 • 2019 ACR/ARP Annual Meeting
The MUC5B Promoter Variant Does Not Predict Outcomes in Systemic Sclerosis-related Interstitial Lung Disease
Elizabeth Volkmann¹, Donald Tashkin ², Michael Roth ³, Ning Li ², Grace Kim ², Jonathan Goldin ², Maureen Mayes ⁴, Julio Charles ⁵, Philip Clements ², Daniel Furst ⁶, Dinesh Khanna ⁷, Robert Elashoff ² and Shervin Assassi ⁴, ¹University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, ²University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, ³University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁴Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, Texas, USA, Houston, TX, ⁵University of Texas, Houston, Houston, ⁶University of California, Los Angeles, CA, ⁷Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor
Background/Purpose: Interstitial lung disease (ILD) affects the majority of patients with systemic sclerosis (SSc). The disease course of ILD varies among SSc patients and no…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].